Drugs / IBI3014
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06974812 | Apr 2025 → Jun 2026 overdue | — | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Innovent Biologics (Suzhou) Co. Ltd. | Results 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs innoventbio.com ↗
IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. |
| 2025-03-27 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting innoventbio.com ↗
IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Innovent Biologics (Suzhou) Co. Ltd. | 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs innoventbio.com ↗ |
| 2025-03-27 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06974812 ↗ |
| Route | Intravenous | “12 mg/kg D1 IV Q3W” NCT06974812 ↗ |